Bispebjerg Hospital
- Address
- lock Available on a paid plan
Respiratory Tract Diseases
At Bispebjerg Hospital, the Department of Lung Medicine L is running clinical research focused on respiratory tract diseases, especially chronic obstructive pulmonary disease. These studies aim to understand whether new treatment approaches can reduce flare-ups, improve symptoms, and support better long-term control for people living with persistent lung disease.
- Studies in COPD and severe COPD with frequent exacerbations
- Evaluation of new therapies designed to lower the risk of worsening respiratory symptoms
- Research on long-term treatment effectiveness and safety in chronic lung disease
This work reflects a strong clinical focus on improving care for patients with difficult-to-manage chronic respiratory conditions and reducing the burden of repeated exacerbations.
Virus Diseases
The site also participates in research on virus diseases, with a particular emphasis on COVID-19 and other acute respiratory infections in hospitalized adults. These trials are designed to test whether new antiviral or immune-based strategies can improve recovery, strengthen outcomes, and help patients recover more quickly alongside standard care.
- COVID-19 studies in hospitalized patients
- Trials assessing antiviral treatment and immune modulation strategies
- Research aimed at improving clinical recovery and treatment effectiveness
Through platform-based studies such as STRIVE, investigators are helping advance evidence for better management of serious respiratory infections and viral emergencies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 16 therapeutic areas and 15 of 128 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 117 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
- 1Region Hovedstaden7active
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Region Hovedstaden11trials
lock +13 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 111 other sites in Denmark
Therapeutic Area Benchmark — Denmark
Select a therapeutic area to compare against other sites in Denmark.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Denmark
Market Share
Country: Denmark
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Bispebjerg Hospital
lock Showing 1 of 58 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Adaptive, Randomized, Controlled Trial Platform to Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized Patients with Respiratory Infections: Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE) - Shionogi Protease Inhibitor (S-217622) | University Of Minnesota | Phase III | Not Recruiting | Jul 2023 | Oct 2025 |
IMP list
lock Showing 1 of 128 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Sodium Chloride | 5 | Unknown | 2023-02-06 | 2025-03-03 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.